Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OncoCyte Corp (OCX)
NASDAQ:OCX
Holding OCX?
Track your performance easily
OCX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.29 - $4.31
Previous Close$2.71
Volume8.53K
Average Volume (3M)34.60K
Market Cap
$45.62M
Enterprise Value$42.22M
Total Cash (Recent Filing)$3.40M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 27, 2025EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.43
Shares Outstanding16,835,247
10 Day Avg. Volume106,151
30 Day Avg. Volume34,603
Standard Deviation0.24
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)4.74
Price to Sales (P/S)60.55
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue38.00
Enterprise Value/Gross Profit84.28
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$4.25Price Target Upside60.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
OncoCyte News
PremiumCompany Announcements
OncoCyte Corp Reports Q3 2024 Earnings and Strategic Updates
PremiumCompany Announcements
OncoCyte Shareholders Approve Incentive Plan and Meeting Adjournment
PremiumCompany Announcements
OncoCyte Secures Funding Through Private Share SaleBulls Say, Bears Say
Bulls Say
International ExpansionOCX initiated shipping its GraftAssure RUO kidney kit to transplant centers and research universities in the U.S., Asia, and Europe.
Market PotentialThe transplant rejection diagnostics market is large and growing rapidly and OCX's GraftAssure and VitaGraft tests can capture significant market share and serve as strong growth drivers.
Strategic PartnershipsOCX has partnered with Bio-Rad Laboratories to commercialize its GraftAssure and VitaGraft tests and BIO has taken a ~9% stake in OCX.
Bears Say
Cash UtilizationOCX used approximately $5.5M of cash in Q3 and ended the period with around $14M, which is estimated to cover only 2-3 quarters of cash needs.
Revenue PerformanceOCX's Q3'24 revenue of $0.1M came in below consensus' $0.2M.
Revenue ShortfallOCX's Q2'24 revenue of $0.1M was also below the expected $0.3M, indicating a pattern of underperformance.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCX FAQ
What was OncoCyte Corp’s price range in the past 12 months?
OncoCyte Corp lowest stock price was $2.29 and its highest was $4.30 in the past 12 months.
What is OncoCyte Corp’s market cap?
Currently, no data Available
When is OncoCyte Corp’s upcoming earnings report date?
OncoCyte Corp’s upcoming earnings report date is Mar 27, 2025 which is in 120 days.
How were OncoCyte Corp’s earnings last quarter?
OncoCyte Corp released its earnings results on Nov 12, 2024. The company reported -$0.402 earnings per share for the quarter, beating the consensus estimate of -$0.437 by $0.035.
Is OncoCyte Corp overvalued?
According to Wall Street analysts OncoCyte Corp’s price is currently Undervalued.
Does OncoCyte Corp pay dividends?
OncoCyte Corp does not currently pay dividends.
What is OncoCyte Corp’s EPS estimate?
OncoCyte Corp’s EPS estimate is -$0.43.
How many shares outstanding does OncoCyte Corp have?
OncoCyte Corp has 16,835,247 shares outstanding.
What happened to OncoCyte Corp’s price movement after its last earnings report?
OncoCyte Corp reported an EPS of -$0.402 in its last earnings report, beating expectations of -$0.437. Following the earnings report the stock price went down -2%.
Which hedge fund is a major shareholder of OncoCyte Corp?
Among the largest hedge funds holding OncoCyte Corp’s share is Defender Capital, LLC.. It holds OncoCyte Corp’s shares valued at 169K.
---
OncoCyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (60.98% Upside)
$4.25 (60.98% Upside)
Hedge Fund Trend
Increased
By 4.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.73%
12-Months-Change
Fundamentals
Return on Equity
-165.32%
Trailing 12-Months
Asset Growth
-13.94%
Trailing 12-Months
Company Description
OncoCyte Corp
OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.
---
OCX Earnings Call
Q3 2024
0:00 / 0:00
---
OCX Stock 12 Month Forecast
Average Price Target
$4.25
▲(60.98% Upside)
Technical Analysis
Best Analysts Covering OCX
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-55.49%
reiterated a buy rating 14 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -55.49% per trade.
---